期刊文献+

二甲双胍与出生缺陷的关系——Meta分析 被引量:1

原文传递
导出
摘要 二甲双胍(metformin)为双胍类药物,是FDA药品妊娠用药分级中的B类。该药是最常用的抗高血糖药物,可用于2型糖尿病和多囊卵巢综合征(polycysticovarysyn—drome,PCOS)引起的不孕症。因其增加胰岛素受体的数量而不增加其分泌,所以治疗过程中孕妇低血糖的发生率相对低。
出处 《中华围产医学杂志》 CAS 2009年第6期452-453,共2页 Chinese Journal of Perinatal Medicine
基金 武汉市科技局攻关项目(200760423158)
  • 相关文献

参考文献20

  • 1Botta RM. Congenital malformations in infants of 517 pregestational diabetic mothers. Ann 1st Super Sanita, 1997,33 : 307- 311.
  • 2Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol,2004,115:125-133.
  • 3McCarthy EA, Walker SP, McLachlan K, et al. Metformin in obstetric and gynecologic practice:a review. Obstet Gynecol Surv,2004,59:118-127.
  • 4赵明,刘志民.二甲双胍药理作用研究新进展[J].解放军药学学报,2003,19(5):370-372. 被引量:23
  • 5康德英,洪旗,刘关键,王家良.Meta分析中发表性偏倚的识别与处理[J].中国循证医学杂志,2003,3(1):45-49. 被引量:200
  • 6Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med, 2000, 17:507-511.
  • 7Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endoerinol Metab, 2002, 87 : 524-529.
  • 8Glueck CJ, Goldenberg N, Pranikoff J, et al. Height,weight,and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod, 2004,19 : 1323-1330.
  • 9Vanky E, Salvesen KA, Heimstad R, et al. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women;results of a randomized study. Hum Reprod, 2004, 19:1734-1740.
  • 10Ekpebegh CO, Coetzee EJ, van der Merwe L, et al. A 10-year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med, 2007,24 : 253-258.

二级参考文献74

共引文献304

同被引文献14

  • 1丁倩.益生菌制剂的临床应用[J].天津药学,2005,17(1):56-58. 被引量:27
  • 2国务院.国务院关于印发医药卫生体制改革近期重点实施方案(2009-2011年)的通知[Z].国发[2009]12号.
  • 3Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure[J]. Pharmacoeco- nomics, 2003,21 (2) : 89.
  • 4Lexchin J, Grootendorst E Effects of prescription drug us- er fees on drug and health services use and on health sta- tus in vulnerable populations: a systematic review of the evidence[J]. International Journal of Health Services, 2004,34(1) : 101.
  • 5Morton-Jones TJ, Pringle MA. Prescribing costs in dispe- nsing practices[J]. BMJ, 1993,306(6 887) : 1 244.
  • 6Cuellar AE, Gertler PJ. Strategic integration of hospitals and physicians[J]. Journal of Health Economics, 2006,25 (1):1.
  • 7Harbarth S, Samore MH, Lichtenberg D, et al. Prolong- ed antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resis- tance[J]. Circulation, 2000,101(25) :2 916.
  • 8Saavedra JM. Clinical applications of probiotic agents[J]. Am J Clin Nutr,2001,73(6) : 1 147s.
  • 9王健,赵君利.促排卵药物的合理应用[J].中国医院药学杂志,2008,28(14):1205-1208. 被引量:10
  • 10刘利群,王迪飞,张新平.药事服务费用水平及其影响因素分析[J].医学与社会,2009,22(6):7-8. 被引量:39

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部